Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen | Zendy

Mariana Gerschenson | Zendy; Courtney Kim | Zendy; Baiba Berzins | Zendy; Babafemi Taiwo | Zendy; Daniel Libutti | Zendy; Julia Choi | Zendy; Diana Chen | Zendy; Jill Weinstein | Zendy; Jessica Shore | Zendy; Bárbara da Silva | Zendy; E M Belsey | Zendy; Grace A. McComsey | Zendy; Robert L. Murphy | Zendy

Open Access

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen

Author(s) -

Mariana Gerschenson,

Courtney Kim,

Baiba Berzins,

Babafemi Taiwo,

Daniel Libutti,

Julia Choi,

Diana Chen,

Jill Weinstein,

Jessica Shore,

Bárbara da Silva,

E M Belsey,

Grace A. McComsey,

Robert L. Murphy

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp100

Subject(s) - stavudine , lopinavir , lamivudine , zidovudine , lipoatrophy , mitochondrial toxicity , medicine , reverse transcriptase inhibitor , endocrinology , ritonavir , mitochondrion , biology , pharmacology , viral load , immunology , biochemistry , virus , antiretroviral therapy , hepatitis b virus , viral disease

HIV-associated lipoatrophy has been associated with mitochondrial dysfunction induced by nucleoside reverse transcriptase inhibitor therapy. We hypothesize that lipid profiles and markers of mitochondrial function will improve in HIV-lipoatrophic patients switched to the nucleotide analogue tenofovir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research